Antineoplastic Combined Chemotherapy ProtocolsRadiation InjuriesChemotherapy, AdjuvantRadiation DosageRadiation, IonizingCombined Modality TherapyDose-Response Relationship, RadiationRadiotherapyRadiotherapy DosageRadiation ToleranceTreatment OutcomeRadiationAntineoplastic AgentsCisplatinRadiotherapy, ConformalRadiation OncologyRadiation ProtectionRadiotherapy, AdjuvantRadiotherapy, Intensity-ModulatedRadiation MonitoringDoxorubicinCyclophosphamideNeoplasm StagingDose FractionationDisease-Free SurvivalBreast NeoplasmsNeoplasm Recurrence, LocalSurvival AnalysisNeoadjuvant TherapyRadiation PneumonitisSurvival RateRadiotherapy Planning, Computer-AssistedPrognosisBrachytherapyLung NeoplasmsEtoposideBrain NeoplasmsNeoplasmsNeoplasms, Radiation-InducedCranial IrradiationRadiometryDrug Administration ScheduleRadiation Injuries, ExperimentalRadiation-Sensitizing AgentsFollow-Up StudiesRadiosurgeryCarboplatinHead and Neck NeoplasmsTime FactorsMethotrexateVinblastinePaclitaxelGamma RaysAdenocarcinomaCosmic RadiationChemoradiotherapyCarcinoma, Squamous CellBleomycinRadiotherapy, Computer-AssistedCarcinoma, Non-Small-Cell LungHodgkin DiseaseRadiotherapy, High-EnergyInduction ChemotherapyParticle AcceleratorsSalvage TherapyDacarbazineRadiotherapy, Image-GuidedRadiation-Protective AgentsAntineoplastic Agents, AlkylatingTaxoidsAntimetabolites, AntineoplasticRadiodermatitisDeoxycytidineTomography, X-Ray ComputedNeoplasm MetastasisIfosfamideBackground RadiationDrug Resistance, NeoplasmActuarial AnalysisKaplan-Meier EstimateOrganoplatinum CompoundsProspective StudiesClinical Trials as TopicOrgans at RiskSarcomaCobalt RadioisotopesMastectomy, SegmentalBone NeoplasmsLomustineLymphoma, Non-HodgkinCell Line, TumorProstatic NeoplasmsUltraviolet RaysPalliative CareNeoplasms, Second PrimaryTesticular NeoplasmsRadiation EffectsAnthracyclinesLymphatic MetastasisCytarabine